Tirzepatide Protocol

Dosing & Research

Last Updated: September 4, 2026

Chemical Identity

Molecular Formula: C225H348N48O68
Molecular Weight: 4813.45 g/mol
CAS Number: 2023788-19-2

Diabetes and obesity research, GIP/GLP-1 dual agonist pharmacology, Weight-loss outcomes, Cardiometabolic studies

Evidence Level

Human Clinical Data Available

Species Studied

Human • Rat • Mouse

Half-Life

~5 Days

Administration

Subcutaneous

Frequency

Once Or Twice Weekly, Same Day(s) Each Week

How It Works

Diabetes and obesity research
GIP/GLP-1 dual agonist pharmacology
Weight-loss outcomes
Cardiometabolic studies

Dosing Structure

Dose

2.5–5.0 mg weekly (up to 7.5 mg)

Frequency

Once Or Twice Weekly, Same Day(s) Each Week

Notes

1x Weekly titration: Week 1-4: 2.5mg | Week 5-8: 5mg | Week 9-12: 7.5mg | Week 13-16: 10mg | Week 17-20: 12.5mg | Week 21+: 15mg. 2x Weekly titration: Week 1-4: 1.25mg | Week 5-8: 2.5mg | Week 9-12: 3.75mg | Week 13-16: 5mg | Week 17-20: 6.25mg | Week 21+: 7.5mg. No need to increase dose if experiencing benefits. Inject: Thigh, abdomen (2+ inches from navel), upper arm. Any time of day, with or without food. Medical supervision required for discontinuation. Typically follows a weekly titration schedule.

Example Protocols

Dose: 2.5–5.0 mg weekly (up to 7.5 mg)

Frequency: Once Or Twice Weekly, Same Day(s) Each Week

Duration: 8-48 weeks

Off Period: Not listed

Calculate dosing →

Find Research Grade Tirzepatide

Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.

Vendor One Research Labs

COA Verified

Third-party COA-verified research peptides with published batch testing.

Source Coming Soon

Vendor Two Sciences

Purity Tested

US-based research compound supplier with independent purity testing.

Source Coming Soon

Vendor Three Peptide Co.

Bulk research peptide sourcing with batch-level documentation.

Source Coming Soon

View all recommended vendors →

Protocol Notes

1x Weekly titration

Week 1-4: 2.5mgWeek 5-8: 5mgWeek 9-12: 7.5mgWeek 13-16: 10mgWeek 17-20: 12.5mgWeek 21+: 15mg

2x Weekly titration

Week 1-4: 1.25mgWeek 5-8: 2.5mgWeek 9-12: 3.75mgWeek 13-16: 5mgWeek 17-20: 6.25mgWeek 21+: 7.5mg

•

No need to increase dose if experiencing benefits.

•

Inject: Thigh, abdomen (2+ inches from navel), upper arm.

•

Any time of day, with or without food.

•

Medical supervision required for discontinuation.

•

Typically follows a weekly titration schedule.

What Is Tirzepatide?

Tirzepatide is a once-weekly injectable drug that activates two gut hormone receptors simultaneously - GIP and GLP-1 - to reduce appetite, slow digestion, and improve blood sugar regulation. It was approved by the FDA in 2022 for type 2 diabetes and in 2023 for chronic weight management, and produced the largest weight loss numbers ever recorded in a pharmaceutical trial at the time of approval.

Research Observations - Not Medical Claims

▸SURMOUNT-1 (NEJM, 2022; PMID: 35658024): Adults with obesity (no diabetes) on 15 mg/week lost an average of 22.5% of body weight over 72 weeks vs. 2.4% for placebo.
▸SURPASS-2 (NEJM, 2021; PMID: 34170647): At 15 mg, tirzepatide reduced HbA1c by 2.46% vs. 1.86% for 1 mg semaglutide - statistically superior.
▸SURMOUNT-2 (Lancet, 2023): In adults with T2D and obesity, the 15 mg dose produced 15.7% mean weight reduction over 72 weeks.
▸Liver fat: A substudy showed tirzepatide reduced liver fat content by up to 54% in metabolic-dysfunction-associated steatohepatitis (MASH) models.
▸Cardiovascular: SURPASS-CVOT showed 14% reduction in major adverse cardiovascular events vs. insulin degludec in T2D patients.